
Please try another search
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company is headquartered in Boulder, Colorado.
Name | Age | Since | Title |
---|---|---|---|
Andrew J. Phillips | 53 | 2021 | Independent Chairman |
Nicholas A. Saccomano | 65 | 2021 | President, CEO & Director |
Isaac Manke | 48 | 2021 | Independent Director |
Valerie Malyvanh Jansen | 47 | 2024 | Independent Director |
Michael G. Grey | 72 | 2024 | Director |
Edward T. Mathers | 65 | 2024 | Independent Director |
R. Michael Carruthers | 67 | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review